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Abstract
Background: Single-sided deafness (SSD) describes the presence of a unilateral severe to profound sensorineural
hearing loss. SSD disrupts spatial hearing and understanding speech in background noise. It has functional,
psychological and social consequences. Potential options for rehabilitation include hearing aids and auditory
implants. Benefits and harms of these interventions are documented inconsistently in the literature, using a variety
of outcomes ranging from tests of speech perception to quality of life questionnaires. It is therefore difficult to
compare interventions when rehabilitating SSD. The Core Rehabilitation Outcome Set for Single Sided Deafness
(CROSSSD) study is an international initiative that aims to develop a minimum set of core outcomes for use in
future trials of SSD interventions.
Methods/design: The CROSSSD study adopts an international two-round online modified Delphi survey followed
by a stakeholder consensus meeting to identify a patient-centred core outcome domain set for SSD based on what
is considered critical and important for assessing whether an intervention for SSD has worked.
Discussion: The resulting core outcome domain set will act as a minimum standard for reporting in future clinical
trials and could have further applications in guiding the use of outcome measures in clinical practice.
Standardisation will facilitate comparison of research findings.
Keywords: Consensus methods, Core outcome set, Delphi technique, Single-sided deafness
Background
‘Single-sided deafness’ (SSD) is the name given to the
condition in which there is normal or near-normal hearing
in one ear and a severe to profound hearing impairment in
the other ear [1]. SSD can be congenital, sudden or
progressive. The most common causes of SSD in adulthood
are sudden and idiopathic, including vestibular schwan-
noma [2] and associated surgery [3], Ménière’s disease [4],
and sudden-onset sensorineural hearing loss [5]. The
incidence of SSD in the United Kingdom is estimated to be
approximately 9000 new cases per year [6].
Good hearing in both ears helps people to deal with
everyday listening tasks [7]. These include understanding
speech in noisy environments and locating where
sounds, such as the telephone or car traffic, are coming
from [8, 9]. In adults with SSD, both these abilities are
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compromised [10–14] and can lead to functional [15],
psychological and social consequences [16, 17]. The
multi-dimensional burden on overall health is indicated
by reductions in health-related quality of life [18] in
individuals with a diagnosis of SSD.
The most commonly used treatments for SSD restore
two-sided (bilateral) access to sounds by re-routing
sounds from the impaired ear to the hearing ear [19].
This can be achieved with the help of a specialised hear-
ing aid system known as the CROS (contralateral rout-
ing of signals) aid [20]. Bone-anchored hearing aids
(BAHA) have also been used as interventions for SSD to
achieve signal re-routing [21]. Alternatively, an auditory
prosthesis such as a cochlear implant can deliver infor-
mation about sounds directly to the auditory pathway on
the side of the impaired ear, thus creating a sensation of
true ‘binaural’ hearing [12].
Existing literature has highlighted inconsistencies in
what benefits and risks (side effects) are assessed when
evaluating these interventions [22]. The different sorts
of benefits and risks are collectively called ‘outcomes’
[23]. For example, researchers have measured aspects
or outcomes such as speech understanding in quiet
[24–28] or noise [12, 24, 26–45], sound localisation [12,
20, 24, 27–29, 32, 36–41, 43, 44, 46–50], the impact on
the recipients’ quality of life [29, 47, 51] or tinnitus ef-
fects [12, 31, 52–60]. These inconsistencies in out-
comes used in the field of SSD and the variety of
methods used to measure them have been identified as
a major barrier to synthesising evidence across trials
[61]. This diversity in outcomes and instruments used
also hinders researchers in making decisions about the
choice of outcome measures for health and social care
trials of clinical efficacy [23, 62, 63].
The importance of using valid instruments that effect-
ively measure the intended audiological outcomes has
been highlighted by Hall et al. [64]. Triallists should
ideally base the choice of outcome measures on what is
important and of interest to people making decisions
about healthcare [65–67], not on what outcome instru-
ments are available or most commonly used [68]. If evi-
dence is lacking for an important outcome, this should
be acknowledged rather than ignoring the outcome [23].
A core outcome set (COS) developed from the perspec-
tives of healthcare users [69, 70], healthcare profes-
sionals and other relevant stakeholders would overcome
this problem [71–74].
A COS is defined by COMET (Core Outcome
Measures for Effectiveness Trials) as ‘an agreed mini-
mum set of outcomes or outcome measures’ [75]. A
COS comprises a standardised collection of outcome
domains that should be measured and reported world-
wide, at minimum, in all controlled trials within a
research area [63, 76–78], as well as a recommended
measurement instrument for each outcome domain. An
internationally adopted COS allows study findings in a
specific health area or condition to be combined, com-
pared and contrasted across trials. It also reduces poten-
tial for reporting bias and ensures that the data are
useful and usable, which is essential for making well-
informed healthcare choices [23].
One of the earliest examples of an attempt to stand-
ardise outcomes is an initiative by the World Health
Organisation in the 1970s relating to cancer trials [79].
More recent projects are the IMMPACT (Initiative on
Methods, Measurement, and Pain Assessment in Clinical
Trials) study for chronic pain [80], the OMERACT
(Outcome Measures in Rheumatoid Arthritis Clinical
Trials) consensus initiative for many rheumatologic con-
ditions [81], the HOME (Harmonizing Outcome
Measures for Eczema) framework in dermatology [82],
the GASTROS (Standardising Outcome Reporting in
Gastric Cancer Surgery Research) study for reporting
outcomes in gastric cancer surgery [83], and the COMi-
T’ID (Core Outcome Measures in Tinnitus International
Delphi) initiative for chronic subjective tinnitus [84]. It
is vital that all stakeholders, such as healthcare users,
with lived experience of the condition, as well as health-
care professionals, commercial representatives or budget
holders, are involved in the development of relevant
COS [23, 85].
Aims
The primary aim of the Core Rehabilitation Outcome
Set for Single Sided Deafness (CROSSSD) study is to
develop an agreed minimum set of outcome domains
relevant to both patients and professionals that should
be measured and reported in all future trials examining
SSD interventions, regardless of whether the interven-
tion restores two-sided (bilateral) access to sound via the
better ear or delivers sound information directly to the
impaired ear.
The primary objective is as follows:
 To develop an international consensus on a COS for
SSD interventions using a long-list list of candidate
outcomes, a two-round modified electronic Delphi
survey and a subsequent face-to-face consensus
meeting with relevant stakeholders
To assist in identifying potential measurement instru-
ments for each core outcome domain identified in the
first objective, two secondary objectives are as follows:
 To synthesise the evidence on the available outcome
measurement instruments for measuring the
construct outcomes (e.g., speech perception,
localisation) in the COS for SSD interventions
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 To follow up on any issues raised during the Delphi
process concerning the concept definition of any of
the outcome domains in a subsequent face-to-face
workshop involving healthcare users and healthcare
professionals
Methods/design
This study will adopt recommendations by the COMET
Initiative [63, 72, 86–88] and the COMET Handbook
version 1.0 [23] '(see Additional file 2 COS-STAP check-
list). We will use a modified e-Delphi process to achieve a
consensus of opinion among broadly representative and
international expert stakeholder groups [89]. This study
uses an observational design and is sponsored by the Uni-
versity of Nottingham and managed by the National Insti-
tute for Health Research (NIHR) Nottingham Biomedical
Research Centre (BRC). A prospective study protocol was
registered on the COMET database in January 2018 [90].
This paper describes protocol version 2.0 (dated 6th July
2019) that was approved by the Proportionate Review
Nottingham 2 Research Ethics Committee (REC reference
19/EM/0222, IRAS Project ID 239750) on the 6th of
August 2019.
Research steering group
A research steering group was appointed in October
2017 to guide the protocol development and oversee the
CROSSSD study. The group comprises international col-
leagues who are experts in SSD research methodologies
and intervention approaches (PVH, JBF, IAB); a patient
and public involvement (PPI) and engagement manager
(AH); two healthcare users with lived experience of SSD,
referred to as public research partners (NB, NH); and
the study management team (RK, DAH, PTK).
The roles of the research steering group are as follows:
1. Support the development of the study protocol,
specifically commenting on the feasibility of the
modified Delphi process, reviewing study
documentation (e.g., advertisements, information
leaflets, supporting video explanations of the
survey and intended advertisements, website
content) and participating in a pilot of round 1
of the e-Delphi survey
2. Review the initial list of outcome domains and
associated descriptions, specifically commenting on
the readability of the outcome descriptions, the
appropriateness of the grouping of outcomes into
categories and providing any additional outcomes
that they believe should be included in round 1 of
the e-Delphi survey
3. Assist with participant recruitment and engage in
dissemination activities, such as contributing to
publications
4. Consider any necessary revisions to the protocol
which may inadvertently arise while the study is
underway
Eligibility criteria for Delphi panels
A range of expertise within the panel is an important
quality criterion for development of a core outcome
domain set [23]. Specific inclusion criteria have been
defined for three key stakeholder groups:
1. Healthcare users who have experience of living with
SSD for 12 months or more and have received or
have considered receiving an SSD intervention
2. Healthcare practitioners who have a clinical
qualification, are currently employed by a public or
private institution that provides SSD interventions
to patients and have experience of assessing,
diagnosing or managing SSD in adults
3. Clinical researchers who have an academic
qualification, are currently employed by a research
organisation, have current or ‘recent past’
experience with studies that focus on questions of
clinical efficacy (benefit) of SSD interventions in
humans (i.e., co-author on a relevant peer-reviewed
journal publication in the past 3 years)
Other participants will be invited to participate,
including those commercial representatives who are
currently employed by a company that develops, manu-
factures or sells product(s) that may be used as an SSD
intervention, as well as funders who are currently
employed by an organisation that funds SSD research
and have experience of reviewing funding applications
for SSD intervention research in the last 3 years. How-
ever, we do not anticipate recruiting sufficient numbers
from among these stakeholders to form distinct stake-
holder groups in their own right, because these pods of
stakeholders are small.
General eligibility for participation includes men and
women aged 18 years or older who are computer-
literate; possess sufficient command of English to read,
understand and independently complete the question-
naires; and have the ability to give informed consent. All
enrolled e-Delphi panellists will be eligible to register
their interest in attending a 1-day face-to-face consen-
sus meeting and/or a follow-up workshop. However,
allocation of places will be limited to those respon-
dents who complete both rounds of the e-Delphi
survey. None of the research steering group members
will be allowed to vote on domains in the consensus
meeting, because this risks inadvertently introducing a
power differential across participants; however, they
can enrol in the e-Delphi surveys.
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Panel size and justification
There is no agreed method to statistically calculate a
sample size for e-Delphi surveys or consensus meetings
[85]. However, one of the key deciding factors is that the
participant panel membership should adequately repre-
sent corresponding stakeholder groups. Adult SSD is a
relatively rare hearing disorder, with approximately 9000
new cases diagnosed in the United Kingdom each year
[6]. SSD intervention is also a relatively new field, espe-
cially cochlear implantation, which has been used in this
population only in the last decade [91]. Therefore, the
number of professionals and members of the public with
knowledge and experience of these interventions is lim-
ited. The aim is therefore to recruit a sufficient number
of participants so that a minimum of 20 participants
complete the two rounds of the e-Delphi survey in each
of the key stakeholder groups (healthcare users, health-
care practitioners and clinical researchers). This target is
consistent with our previous work [85].
The consensus meeting and follow-up workshop
require in-depth discussions, and therefore up to 20
participants will be recruited for each. Enrolment will be
balanced across stakeholder groups when possible.
Recruitment methods
Effective recruitment methods similar to the ones
described by Hall et al. in 2018 [85] will be used. For
example, adopting an explicit marketing plan and
engaging with charities or participants to act as ‘cham-
pions’ were successful strategies that helped recruitment
for both healthcare users and professionals in the
COMiT’ID study.
Generally, the CROSSSD study recruitment plan includes
e-promotion routes, which include a study webpage
(www.nottingham.ac.uk/research/groups/hearingsciences/
projects/crosssd/index.aspx) and regular updates on the
study’s progress via social media platforms (e.g., Twitter
@CROSSSD_, @hearingnihr). A video advertisement pro-
moting the study will also be developed.
Healthcare users will be targeted using various routes,
including promotion of the study during the Ménière’s
Society Balance Awareness Week (September 2019) and
the British Acoustic Neuroma Association annual con-
ference (October 2019). Moreover, healthcare users in
the United Kingdom and Ireland will be targeted using a
traditional National Health Service (NHS) recruitment
route with 18 audiology and ear, nose and throat (ENT)
departments whose members specialise in provision of
interventions for SSD. These will be designated as
participant identification centres (PICs) and will be in
addition to the lead site in Nottingham. An application
will also be submitted for adoption of the CROSSSD
study into the NIHR Clinical Research Network (CRN)
portfolio, through which other NHS sites can express
their interest to support the study by being a PIC.
PICs will display study posters in the audiology and
ENT clinic waiting rooms and hand out participant
information leaflets, as appropriate. If feasible, partici-
pant invitation letters will be posted by local PIC clini-
cians to their database of patients diagnosed with SSD.
Specific e-promotion routes include several organisa-
tions that have agreed to support the project by publish-
ing newsletter articles and announcements to their
members (e.g., Manchester Hearing BRC volunteers,
Ménière’s Society). Finally, the lead study site, the NIHR
Nottingham BRC, has a participant database containing
email contacts for approximately 70 healthcare users
who have been diagnosed with SSD and will be invited
to participate.
For healthcare professional recruitment, we are aiming
to recruit experts who maximise the international rele-
vance of the study findings [89]. A number of profes-
sional networks and organisations will be approached to
circulate invitations to their membership (e.g., British
Society of Audiology Adult Rehabilitation Interest
Group, HEARRING Network, Hearing Australia). When
possible, the expert members of the CROSSSD steering
group will be asked to approach their networks to make
the approach more personal. Parallel routes for recruit-
ing healthcare professionals will also involve personal
invitation via email or face-to-face contact (e.g., presen-
tations at teams’ monthly journal clubs or research
meetings).
The study management team has created a long list of
potential participants with relevant expertise via existing
connections with the NIHR Nottingham BRC, manual
searches of relevant hearing-related organisations (e.g.,
UHealth Ear Institute at the University of Miami), corre-
sponding authors of the relevant research publications
identified by the systematic review [90], manual searches
of relevant conference proceedings in the last 3 years
(e.g., UK Implantable Acoustic Devices Conference,
International Conference on Cochlear Implants and
Other Implantable Technologies [Ci2018.org], OSSEO
International Congress on Bone Conduction Hearing
and Related Technologies), and email queries sent to
representatives from each additional stakeholder organi-
sations from commercial sectors (e.g., clinical research
managers for relevant device companies) and funding
bodies asking for recipients to nominate any colleagues
with expertise in SSD interventions.
Eligible professionals will be identified and invited to
participate and will be asked a number of questions
which will confirm both their stakeholder group (i.e., job
role or medical specialty) and that they meet the eligibil-
ity criteria for their stakeholder group (see ‘Eligibility cri-
teria for Delphi panels’ section above). Professional
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stakeholder groups include individuals involved in man-
agement or research in the field of SSD. These include
healthcare professionals, clinical researchers, commercial
representatives, funders, and journal editors. These
groups have been identified as those representing the
main professional categories in SSD research and clinical
trials.
Delphi survey
An international Delphi survey will be managed online
using DelphiManager software maintained by the
COMET Initiative [92]. Each panellist will receive a
unique identification code and an e-link to the webpage.
A video explanation will illustrate how to use the online
tool. A flowchart of the study is shown in Fig. 1.
Delivering this study online allows us to capture the
opinions of a diverse population of stakeholders with an
interest in shaping outcome measures for SSD interven-
tions. If any healthcare users do not have home access
to a computer or a tablet, then they will be offered the
option of visiting the NIHR Nottingham BRC to
complete the two online rounds using one of the centre’s
computers.
The e-Delphi technique can minimise response bias
because individual feedback is anonymised and not af-
fected by views of influential individuals [93]. Surveys
can also be perceived as intimidating by members of the
public as a result of the long number of outcomes in-
cluded in some e-Delphi surveys that lay participants
would have to go through and score at every round [94].
Methodological features highlighted by Smith et al. [95],
such as shortening and renaming the long list of do-
mains and plain language descriptions, will be adhered
to when possible. Evaluations discussed by Hall et al.
[85] will be considered to ensure robust recruitment and
retention of healthcare users.
Part 1: Preparatory work to generate the long list of
candidate outcomes
Potentially important outcomes were first gathered from
a systematic review of the literature which identified
those outcome domains and outcome instruments re-
ported in studies investigating interventions that seek to
restore hearing in adults with SSD [96], as well as by
considering published qualitative data [16] derived from
group interviews examining subjective psychological and
social effects of highly asymmetric hearing loss. A work-
shop with members of the research steering group
reviewed this long list of candidate outcomes with the
following objectives:
1. Exclude outcomes that are deemed outside the
scope of this COS
2. Identify any missing outcomes
3. Consider the choice of language used to define each
outcome
4. Generate plain-language descriptions of each
outcome
The CROSSSD study management team collated all
primary and secondary outcomes that were identified by
the systematic review [96], which equated to 216 out-
come domain terms. In preparation for the workshop,
these were categorised into six preliminary groupings:
(1) adverse effects or harms, (2) performance in a test
situation, (3) patient outcome, (4) resource use, (5) satis-
faction and (6) other/cannot code. All individual out-
come domains were printed on cards in preparation for
a 2-day workshop that took place in July 2019 with
Fig. 1 CROSSSD study plans for the development of an internationally agreed core outcome set (COS) for single-sided deafness interventions,
identification of outcome measurement instruments, and adoption and implementation of the COS
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members of the research steering group (RK, DAH, AH,
PTK) and the two public research partners (NH, NB).
During the workshop, each member first performed an
independent rapid review of the individual outcome
domains and marked those that they thought did not fit
within the scope of core domain set for SSD interven-
tions. It was agreed that an outcome domain would be
excluded for not fitting within the scope if all six mem-
bers unanimously agreed to exclude or there was no
more than one dissenting opinion. During this rapid
review, 83 outcome domain terms were excluded, and
examples of those domains were phrases describing
‘how’ to measure such as thresholds, audiologic, tono-
topy, informational masking, cortical changes, and brain
activity; or outcome domains that were deemed too
broad, generic or ill-defined, such as qualities, hearing,
therapy, background noise, mental health, and cognitive
distress. Further group discussion led to consolidation of
an additional 23 outcome domain terms into a smaller
number of outcome domain labels. For example, hearing
disability was considered to be synonymous with
residual disability, perceived hearing disability, hearing
disability at everyday life, and auditory disability.
Another 17 outcome domain terms were deemed to be
duplicates or descriptions of already-included outcome
domains (e.g., subjective assessment of handicap, disabil-
ity, use, benefit, and satisfaction). This left 93 outcome
domains for the long list.
The workshop team next systematically reviewed and
discussed the findings published by Lucas et al. [16] to
determine whether qualitative interviews might have
identified any other candidate outcome domains. This
process added three new outcome domains which had
not been assessed explicitly in previous quantitative
studies: personal safety (e.g., road safety, independent liv-
ing), motivation (e.g., to engage in challenging listening
situations) and mood (e.g., general sense of well-being).
The resulting 96 outcome domains were consolidated
further by grouping domains together that were con-
sidered by the group to describe the same domain.
For example, the outcome domains sound localisation,
localisation, localisation performance, azimuthal sound
localisation, auditory localisation, localisation ability,
source localisation, localisation testing, and ability to
judge direction of sound were consolidated into an
outcome domain labelled ‘sound localisation (telling
where a sound is coming from)’. This consolidation
resulted in a final list of 43 outcome domains, which
were subsequently organised thematically into ten ca-
tegories: (1) psychological effects, (2) factors related to
the treatment being tested, (3) health-related quality
of life, (4) hearing disability, (5) spatial hearing, (6)
physical effects, (7) self, (8) sound quality, (9) tinnitus
and (10) other effects (Fig. 2).
Some of the outcome domains were the same as had
been defined in our previous work on tinnitus [84] and
hearing loss [97], so we used the same plain-language
descriptors when appropriate. Others required plain-
language descriptors to be developed through interactive
discussion during the workshop.
The long list of outcome domains, labels and plain-
language descriptors were subsequently circulated elec-
tronically to the CROSSSD study steering group for
feedback and cross-checking. This was done to ensure
that the outcome domain concepts were explained in
ways that are understandable and meaningful to an
international audience, especially to those whose first
language is not English. The research steering group was
also prompted to suggest any missing candidate out-
come domains. The study management group used this
feedback and, following further revisions to the long list,
prepared a final list of 44 candidate outcome domains
that will be incorporated into the e-Delphi survey (see
Additional file 1 for the final list of outcome domains
and their definitions). The randomisation feature of the
DelphiManager software (version 4.0) will be used to
avoid potential weighting [98]; that is, presentation of
each outcome domain will be randomised as per current
recommendations [23, 99].
Part 2: Outcome prioritisation and consensus decision-
making
The modified e-Delphi survey comprises a series of two
sequential questionnaires or ‘rounds’ aiming to obtain a
consensus of opinion from professional and healthcare
user stakeholder groups. Each Delphi survey will be
managed using a bespoke online e-management system
(DelphiManager software, version 4.0) maintained by the
COMET Initiative [92]. Both survey rounds will contain
a questionnaire that includes the final long list of cate-
gorised outcome domains (n = 44) developed in part 1.
International healthcare users and professionals with
experience in receiving or managing SSD interventions
will be identified and invited to take part (see ‘Recruitment
methods’ section above for details).
Upon entering the online survey webpage, an intro-
ductory page will reiterate key information previously
provided in the participant information sheet, including
an embedded link to a video explanation. Participants
will then be asked to give informed consent, and a
unique identification code will be generated to allow
tracking of individual responses in round 2. Video
explanations will guide participants through the round.
Following this, participants will complete a checklist of
relevant personal characteristics. These include personal
and/or professional experience with SSD interventions;
treatments trialled, if applicable (e.g., BAHA, CROS); the
group they primarily identify with (e.g., healthcare users,
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healthcare practitioners, clinical researchers, commercial
representatives, funders); age range; gender; country of
residence; primary language used for communication;
professional role (if applicable); length of SSD diagnosis
and interventions primarily used (for healthcare users);
and email address.
The survey will be piloted by the study management
team and public research partners for face validity, un-
derstanding and acceptability. Following this, if needed,
modifications will be made before finalising and launch-
ing the questionnaire. When the first round of the e-
Delphi survey is launched, participant recruitment will
commence immediately, and the recruitment period will
be for at least 2 months. Participant response rates will
be monitored throughout, and the study management
team will keep clearly defined records of the number of
participants who have completed the rounds and those
who have not.
Round 1
For each of the 44 outcome domains, participants will
be asked to think about the importance of each and indi-
cate how important it is to measure when deciding if an
intervention is working. Participants will be asked to
assign a score to each of the 44 candidate outcome
domains. A 9-point Likert scoring system will be used,
with a score of 1 to 3 signifying that an outcome domain
is of limited importance, 4 to 6 indicating important but
not critical, and 7 to 9 meaning critical and important
[100]. Participants will be made aware that an outcome
domain will be considered for inclusion in the COS only
if 70% or more of the participants in each of the stake-
holder groups select scores 7–9 on the scale. If a partici-
pant feels that (s)he did not understand a particular
outcome, (s)he will be able to select ‘unable to score’.
Following each outcome and at the end of the ques-
tionnaire, each participant will be offered an open-text
box to add any comments about particular outcome
domains. This is optional, but participants will be
encouraged to provide a reason for their scores on indi-
vidual outcomes as recommended by the COMET
Handbook [23]. These comments will be summarised as
part of the feedback after the first round.
In round 1, participants will be able to propose additional
outcome domains. These additional outcome domains will
be reviewed and coded by the study management team
members, with appropriate plain-language concept defini-
tions, to ensure that they represent new items for inclusion
Fig. 2 CROSSSD study flow diagram illustrating the pre-Delphi stage that has been completed during a workshop with members of the research
steering group
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in round 2. When uncertainty exists, the research steering
group will be consulted, and all new outcome domain
terms, concept definitions and category labels will be
reviewed. Adhering to current recommendations, reporting
of the e-Delphi surveys will describe any new outcomes in-
troduced into the consensus process at the end of round 1,
with reasons [101].
Round 2
Participants will be eligible to continue to round 2 if
they have scored at least 22 (50%) of the outcome
domains in round 1. Corresponding data from those par-
ticipants who responded to fewer than this will be
removed. In round 2, all participants will receive the
same list of outcomes with feedback tailored according
to their key group allocation (healthcare users, health-
care professionals, clinical researchers). Participants who
identify themselves as commercial representatives or
funders when they register will be considered collect-
ively, and feedback on their scores will be reported
separately from the three stakeholder groups.
The purpose of round 2 is to enable participants to
reflect on their scores in light of the viewpoint of their
stakeholder group and the other stakeholder groups in
the e-Delphi survey. Results will be presented graphically
as well as numerically to be readily understood by par-
ticipants. Participants will be asked to re-score the same
list of outcome domains, considering this new informa-
tion. To help give meaning to the 9-point Likert scale
[100], participants will be reminded that individual out-
come domains will be considered for inclusion in the
COS only if 70% of all participants select scores of 7–9
on the scale. The distribution of the new scores for each
outcome domain will then be calculated for each stake-
holder group. Other aspects of design and analysis are
the same as for round 1. After completion of the second
round of the e-Delphi survey, a questionnaire, antici-
pated to take up to 10min to complete, will be emailed
to all participants to collect feedback on their experience
of being a participant.
Consensus meeting
The aim of the consensus meeting is to integrate health-
care users and professional perspectives on outcomes, as
well as to provide final recommendations on an agreed
COS for SSD interventions. Participants who have com-
pleted the two rounds of the e-Delphi survey, responded
to at least 90% of the outcome domains in round 2, and
register an interest in participating in the consensus
meeting will be eligible to participate. Places will be allo-
cated on a first-come, first-served basis. Recruitment will
be guided by methods successfully adopted by Fackrell
et al. [102]; that is, as far as possible, allocated places will
maintain a 50/50 balance across healthcare users
and professionals and will aim to include non-UK,
non–native English language speakers. As far as possible,
the COMET guidance for designing an accessible COS
consensus meeting will be followed [103].
After confirming their attendance to the meeting, par-
ticipants will be sent an email with information on how
to get to the meeting and what to expect, as well as the
participant information sheet again as a reminder. At
the consensus meeting, the research team will discuss
with the participants the aim of the meeting and what
will happen, ensuring that all participants understand
the purpose before consenting and starting the meeting.
An experienced independent moderator will be
recruited to facilitate the consensus meeting discussions
to agree to a final COS. Discussion within the meeting
will include anonymised voting on each outcome as
either ‘in’ or ‘out’ (e.g., using electronic keypads which
will create histograms and descriptive statistics ‘live’, to
be displayed in the meeting). Participants will be given
materials summarising the anonymised round 2 results.
Consensus criteria
Consensus recommendations will be guided by round 2
results. The ‘70/15%’ consensus approach as described
by Williamson et al. [71], and Williamson et al. [23] and
successfully used by Harman et al. [104] and Hall et al.
[84] will be employed, as follows:
 For outcomes recommended to be included on the
basis of round 2 analysis (70% scored 7–9), the
moderator will establish whether anyone has a
major reason to want any to be excluded. The
moderator will focus the discussion and voting on
these outcomes. Domains will be included if at least
70% of participants vote ‘in’. All other outcomes
recommended for inclusion will be ‘in’, without
further discussion.
 For outcomes in which at least 50% of more than
one stakeholder group scored 7–9 on the round 2
analysis, the moderator will focus the discussion and
voting. Domains will be included if at least 70% of
participants vote ‘in’.
 For outcomes in which less than 50% of the
participants in all stakeholder groups scored 1–7 on
the round 2 analysis, the moderator will establish
whether anyone has a major reason to want any to
be included. Domains will be included only if at least
70% of participants vote ‘in’.
If consensus is not reached after two rounds of voting,
a ‘majority rules’ approach will be applied. Because time
for discussion will be limited, there will be no discussion
about outcomes whereby the round 2 data meet the
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criteria for exclusion based on the pre-defined consensus
definition.
The final consensus meeting will be audio recorded
and transcribed to facilitate reporting. These will be
classed as source data and will be retained in the study
archives using unique identifier codes for each talker.
Reporting of the Delphi surveys will list the outcomes in
the final COS [101].
Finally, we will evaluate the participants’ experience of
the consensus meeting using a short evaluation form.
This is adapted and modified from the recommended
template developed by the COMET Initiative [105]. It is
anticipated that completion of this will take approxi-
mately 10 min, and completion is entirely voluntary.
Follow-up workshop
This workshop will be convened only if considered
necessary by the study management team, a judgement
that will be made in consultation with the research
steering group. The aim of the workshop would be to
discuss in more detail any of the outcome domains that
were voted into the core outcome domain set but for
which there might have been some unresolved debate
about what the exact concept of the domain was or how
it was defined in the plain-language descriptor. This will
be important underpinning information to have before
seeking to identify suitable measurement instruments for
each of the outcome domains in the COS.
Analysis
Compliance in the e-Delphi survey will be defined
according to the number of participants completing
rounds 1 and 2. Participation within each stakeholder
group will be assessed, including (1) numbers who were
directly contacted, (2) numbers who registered in the e-
Delphi system, (3) numbers enrolled, and (4) numbers
completing each round. Similar to the methods used by
the mOMEnt (management of Otitis Media with Effu-
sion in children with cleft palate) team [106], if a
reduced number of responders (n < 10) is observed for
one or more stakeholder groups, the round 2 Delphi sur-
vey will be reviewed and revised. For example, we may
consider amalgamating stakeholder groups.
Other analysis will incorporate participant characteris-
tics, such as gender, country, region and native English
language speaker (or not). We will analyse the shifts in
scores between rounds 1 and 2 for each outcome domain
and stakeholder group as a consequence of considering
the anonymised feedback from other participants.
Attrition, referring to the percentage of participants
who withdraw or drop out between rounds, will be
analysed and reported using methods similar to those
employed by the mOMEnt team [106] and the
COMiT’ID team [84]. For example, attrition bias which
might occur if participants who do not respond in round
2 have different views from their stakeholder group peers
who participate in both rounds [23] will be considered
and analysed. To achieve this, methods used by Bruce
et al. [107] can be adopted: Response distributions of
withdrawn and completing participants can be drawn.
Graphical representations by stakeholder group (health-
care users, healthcare professionals, clinical researchers)
can be drawn, too, as presented by Hall et al. [108], to
indicate if attrition bias is likely to have affected the
outcome domain recommendations.
Round 2 score distributions for each outcome domain
will be considered at the final consensus meeting using a
nominal group technique to evaluate individual perspec-
tives. For example, like the methods adopted by Harman
et al. [106], the results of the stakeholder group
responses will be compared with the whole group’s
response, and percentage agreement will be considered
to plan the focus of the consensus meeting [84]. The
data derived from the Delphi feedback questionnaire and
consensus meeting evaluation form will comprise open-
text responses, and these will be analysed using a the-
matic analytic approach.
Dissemination
The project proposal is registered in the COMET Initia-
tive database [90]. Data derived from the final analysis of
the e-Delphi survey, consensus meeting and follow-up
workshop will be presented at relevant national and
international conferences such as the British Society of
Audiology e-conference and the Implantable Acoustic
Devices Conference in Oxford (September 2020). Peer-
reviewed publications resulting from the research are
also planned. We intend to publish the final COS
addressing all primary objectives in the summer of 2020.
This research will be further disseminated to members
of the public and clinicians through specialist magazine
articles and support groups. Participants will not be
identified in any publications.
Discussion
This paper describes the design of a Delphi process to
develop a COS for SSD interventions, comprising an
agreed minimum set of outcome domains relevant to
both patients and professionals. This will be applicable
to all future trials examining SSD interventions, regard-
less of whether the intervention restores two-sided
(bilateral) access to sound via the better ear or delivers
sound information directly to the impaired ear.
During the study protocol development, a question
arose whether to consider developing a single COS for
the two intervention approaches (re-routing/restoring)
or whether to develop separate COSs, one for each
intervention approach. The CROSSSD study research
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steering group was asked to consider the advantages and
disadvantages and to help make a decision.
Advantages of considering both intervention approaches
together were as follows:
 A single COS would set a standard for outcomes
that are critical and important for any of the
common intervention strategies. This would
facilitate comparisons across intervention
methods.
 A single minimum reporting standard may
encourage uptake, minimise the cost and time
resources required, and reflect the fact that SSD is a
relatively small field in otology with a limited
number of clinical trials whose designs and
methodological quality are highly variable [64].
 A single Delphi survey improves confidence with
regard to adequate numbers of stakeholders
recruited internationally to ensure that the decision-
making represents a wider view.
Disadvantages of considering both intervention ap-
proaches together were as follows:
 Outcomes common to both intervention approaches
might be less specific to the unique benefits of either
intervention. The chosen outcomes might not be
optimally sensitive to detecting treatment-related
change.
 Seeking a single COS might reduce the potential for
reaching consensus criteria on individual outcome
domains because the different intervention
approaches can be very different in their intended
effects.
 Few participants are likely to have expertise in both
intervention approaches.
 Two separate Delphi surveys would potentially
deliver a stronger message because they would be
tailored to individual approaches: re-routing and
restoring interventions.
Following thorough consideration of the arguments
put forward, it was agreed to proceed with a single
consensus process to develop one COS that would be
applicable to both intervention approaches. Similar
issues have previously been considered by the
IMMPACT (Initiative on Methods, Measurement, and
Pain Assessment in Clinical Trials) group [109] and led
to the same decision. The IMMPACT team proposed
that development of a single core set of domains and
measurement procedures would facilitate the compari-
son and pooling of data while leaving investigators free
to augment the core domains with other outcomes of
their choice.
To our knowledge, this is the first time that the Delphi
technique using these consensus decision-making
methods has been used for developing a COS in SSD.
This study also heavily incorporates patient and public
involvement throughout all stages of the project. An
agreement on a set of outcome domains for what is crit-
ical and important for deciding whether an intervention
is efficacious will drive up the quality and relevance of
research by ensuring that the most relevant outcomes
are consistently measured and reported in every clinical
trial relating to SSD. This would make it much easier for
people with SSD and their intervening clinicians to make
sense of all the knowledge produced and consequently
minimise bias when making decisions about healthcare.
This should subsequently lead to improvements in SSD
interventions and in turn the management and clinical
outcomes of patients with SSD. On the basis of the rec-
ommended outcome domains, further research will then
be needed to identify measurement instruments that as-
sess the outcome domains in the minimum set.
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